RxDoctor Payments Data

Jeffrey Hatcher, MD

Infectious Disease · Greensboro, NCNPI 1457308918

Payments from drug & device makers

$1,041in general payments, 2019–2025

Across 73 payments — averaging $14.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$372
  • AbbVie$150
  • Gilead$143
  • Merck$84
  • Astellas Pharma US Inc$74
  • Insmed, Inc.$56
  • plus $163 from 7 others

What the payments were for

  • Food & beverage$1,041100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,041 in reported general payments places this provider in the 60th percentile of 250 infectious disease providers in North Carolina.

See all infectious disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$7,331
Medicare patients
53
Services billed
109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala112$472,007
GenvoyaElviteg/Cob/Emtri/Tenof Alafen73$301,169
TriumeqAbacavir/Dolutegravir/Lamivudi56$235,928
JulucaDolutegravir/Rilpivirine44$164,094
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf31$148,673
RukobiaFostemsavir Tromethamine11$97,521
DovatoDolutegravir Sodium/Lamivudine30$95,946
OdefseyEmtricitab/Rilpiviri/Tenof Ala13$47,196
DelstrigoDoravirine/Lamivu/Tenofov Diso13$30,811
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df27$21,942
Darunavir11$4,850
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav11$376
Albuterol Sulfate HfaAlbuterol Sulfate13$312
Zolpidem Tartrate11$126
Amlodipine Besylate12$5

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$143$773,176185 claims
Viiv Healthcare CompanyTriumeq, Juluca, Rukobia, Dovato$372$593,488141 claims
MerckDelstrigo$84$30,81113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 250 infectious disease providers in North Carolina.

Other infectious disease in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →